Unicycive Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . Unicycive Therapeutics
UNCY Stock  USD 0.68  0.09  15.25%   
Unicycive Therapeutics financial statements provide useful quarterly and yearly information to potential Unicycive Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Unicycive Therapeutics financial statements helps investors assess Unicycive Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Unicycive Therapeutics' valuation are summarized below:
Market Capitalization
61.3 M
Enterprise Value Revenue
16.632
Earnings Share
(0.46)
We have found one hundred thirteen available fundamental trend indicators for Unicycive Therapeutics, which can be analyzed and compared to other ratios and to its competition. All investors should make sure to double-check all of Unicycive Therapeutics current market performance against the performance between 2010 and 2024 to make sure the company can sustain itself down the road.

Unicycive Therapeutics Total Revenue

357,720

Check Unicycive Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Unicycive Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 77.9 K, Net Interest Income of 429.4 K or Depreciation And Amortization of 386.4 K, as well as many indicators such as Price To Sales Ratio of 16.04, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. Unicycive financial statements analysis is a perfect complement when working with Unicycive Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Unicycive Therapeutics Correlation against competitors.
For more information on how to buy Unicycive Stock please use our How to Invest in Unicycive Therapeutics guide.

Unicycive Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Current Liabilities18.4 M17.5 M3.7 M
Slightly volatile
Accounts Payable540.1 K821 K264.4 K
Slightly volatile
Total Current Assets14.1 M13.4 M3.3 M
Slightly volatile
Common Stock21.3 K35 K27.3 K
Slightly volatile
Total Assets7.9 M14.2 M2.9 M
Slightly volatile
Short and Long Term Debt Total679.4 K811 K604.4 K
Pretty Stable
Other Current Liabilities17.2 M16.4 M2.5 M
Slightly volatile
Cash And Short Term Investments7.4 M9.7 M3.4 M
Slightly volatile
Common Stock Total Equity9.3 K10.3 K8.4 K
Slightly volatile
Common Stock Shares Outstanding18.7 M24.5 M16.1 M
Slightly volatile
Liabilities And Stockholders Equity7.9 M14.2 M2.9 M
Slightly volatile
Non Current Liabilities Total656.3 K466 K786.4 K
Very volatile
Other Current Assets3.9 M3.7 M789.7 K
Slightly volatile
Other Stockholder Equity63.7 M60.7 M14.8 M
Slightly volatile
Total Liabilities18.9 M18 M3.6 M
Slightly volatile
Short and Long Term Debt17.1 K18 K481.6 K
Very volatile
Capital Stock18 K35 K11.5 K
Slightly volatile
Short Term Debt629 K345 K580 K
Pretty Stable
Property Plant Equipment266.4 K299.7 K326.3 K
Slightly volatile

Unicycive Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative4.4 M8.5 M2.3 M
Slightly volatile
Other Operating Expenses11.8 M21.4 M5.5 M
Slightly volatile
Research Development7.3 M12.9 M3.2 M
Slightly volatile
Total Operating Expenses11.8 M21.4 M5.5 M
Slightly volatile
Income Tax Expense179.2 K116.1 K170 K
Pretty Stable
Cost Of Revenue298.2 K284 K40.1 K
Slightly volatile
Selling And Marketing Expenses227.2 K255.6 K278.3 K
Slightly volatile

Unicycive Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation298.2 K284 K59.9 K
Slightly volatile
Capital Expenditures17.3 K12 K25.3 K
Slightly volatile
End Period Cash Flow4.9 M9.7 M2.1 M
Slightly volatile
Change To Netincome4.7 M4.4 M1.3 M
Slightly volatile
Stock Based Compensation887.9 K1.8 M342.7 K
Slightly volatile
Begin Period Cash Flow432.2 K455 K1.2 M
Slightly volatile
Other Non Cash Items10.8 M10.3 M2.1 M
Slightly volatile
Issuance Of Capital Stock31.7 M30.2 M6.4 M
Slightly volatile
Dividends Paid693.6 K780.3 K849.7 K
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio16.0431.544810.5821
Slightly volatile
Stock Based Compensation To Revenue1.492.61781.228
Slightly volatile
Capex To Depreciation0.04010.04231.7909
Slightly volatile
EV To Sales10.6418.37459.0707
Slightly volatile
Payables Turnover0.00390.00740.0024
Slightly volatile
Sales General And Administrative To Revenue7.8212.66227.3501
Slightly volatile
Research And Ddevelopement To Revenue12.8819.114113.4661
Slightly volatile
Capex To Revenue0.01870.01780.0043
Slightly volatile
Cash Per Share0.250.39530.1944
Slightly volatile
Days Payables Outstanding35.3 K39.7 K43.2 K
Slightly volatile
Income Quality0.520.59860.6651
Slightly volatile
Current Ratio1.390.76420.8006
Slightly volatile
Graham Number1.262.0851.0868
Slightly volatile
Capex Per Share9.0E-45.0E-40.0017
Slightly volatile
Revenue Per Share0.04980.02750.0599
Slightly volatile
Interest Debt Per Share0.00390.00410.1006
Slightly volatile
Debt To Assets0.00120.001324.102
Slightly volatile
Days Of Payables Outstanding35.3 K39.7 K43.2 K
Slightly volatile
Ebt Per Ebit0.931.47031.1552
Pretty Stable
Quick Ratio1.390.76420.8006
Slightly volatile
Net Income Per E B T1.171.151.0754
Slightly volatile
Cash Ratio0.530.55331.1448
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.11.00071.0107
Slightly volatile
Fixed Asset Turnover0.810.85234.8476
Slightly volatile
Debt Ratio0.00120.001324.102
Slightly volatile
Price Sales Ratio16.0431.544810.5821
Slightly volatile
Asset Turnover0.04520.04760.2987
Slightly volatile
Gross Profit Margin0.790.890.9723
Slightly volatile

Unicycive Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap22.1 M21.3 M28.2 M
Slightly volatile
Enterprise Value12.8 M12.4 M13.9 M
Slightly volatile

Unicycive Fundamental Market Drivers

Cash And Short Term Investments9.7 M

Unicycive Upcoming Events

29th of March 2024
Upcoming Quarterly Report
View
21st of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
29th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Unicycive Therapeutics Financial Statements

Unicycive Therapeutics investors use historical fundamental indicators, such as Unicycive Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Unicycive Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue-16.2 K-17 K
Total Revenue675 K357.7 K
Cost Of Revenue284 K298.2 K
Stock Based Compensation To Revenue 2.62  1.49 
Sales General And Administrative To Revenue 12.66  7.82 
Research And Ddevelopement To Revenue 19.11  12.88 
Capex To Revenue 0.02  0.02 
Revenue Per Share 0.03  0.05 
Ebit Per Revenue(30.78)(32.32)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
ESRTEmpire State Realty
CCitigroup
CCitigroup

Additional Tools for Unicycive Stock Analysis

When running Unicycive Therapeutics' price analysis, check to measure Unicycive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Unicycive Therapeutics is operating at the current time. Most of Unicycive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Unicycive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Unicycive Therapeutics' price. Additionally, you may evaluate how the addition of Unicycive Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY